Department of Anesthesiology and Critical Care Medicine, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany.
Center for Evidence-Based Healthcare (ZEGV), University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany.
J Infect Public Health. 2022 Jun;15(6):670-676. doi: 10.1016/j.jiph.2022.05.008. Epub 2022 May 16.
The aim of this study was to describe and compare clinical characteristics and outcomes in critically ill septic patients with and without COVID-19.
From February 2020 to March 2021, patients from surgical and medical ICUs at the University Hospital Dresden were screened for sepsis. Patient characteristics and outcomes were assessed descriptively. Patient survival was analyzed using the Kaplan-Meier estimator. Associations between in-hospital mortality and risk factors were modeled using robust Poisson regression, which facilitates derivation of adjusted relative risks.
In 177 ICU patients treated for sepsis, COVID-19 was diagnosed and compared to 191 septic ICU patients without COVID-19. Age and sex did not differ significantly between sepsis patients with and without COVID-19, but SOFA score at ICU admission was significantly higher in septic COVID-19 patients. In-hospital mortality was significantly higher in COVID-19 patients with 59% compared to 29% in Non-COVID patients. Statistical analysis resulted in an adjusted relative risk for in-hospital mortality of 1.74 (95%-CI=1.35-2-24) in the presence of COVID-19 compared to other septic patients. Age, procalcitonin maximum value over 2 ng/ml, need for renal replacement therapy, need for invasive ventilation and septic shock were identified as additional risk factors for in-hospital mortality.
COVID-19 was identified as independent risk factor for higher in-hospital mortality in sepsis patients. The need for invasive ventilation and renal replacement therapy as well as the presence of septic shock and higher PCT should be considered to identify high-risk patients.
本研究旨在描述和比较伴有和不伴有 COVID-19 的危重症脓毒症患者的临床特征和结局。
2020 年 2 月至 2021 年 3 月,对德累斯顿大学医院外科和内科 ICU 的脓毒症患者进行了筛选。采用描述性方法评估患者特征和结局。使用 Kaplan-Meier 估计器分析患者生存率。采用稳健泊松回归模型对住院死亡率与危险因素之间的关联进行建模,该模型便于推导出调整后的相对风险。
在 177 例因脓毒症接受治疗的 ICU 患者中,诊断出 COVID-19,并与 191 例无 COVID-19 的脓毒症 ICU 患者进行了比较。脓毒症伴 COVID-19 患者和不伴 COVID-19 患者的年龄和性别无显著差异,但 ICU 入院时 SOFA 评分显著更高。COVID-19 患者的住院死亡率显著更高,为 59%,而非 COVID 患者为 29%。统计学分析显示,COVID-19 患者的住院死亡率调整后相对风险为 1.74(95%CI=1.35-2.24)。年龄、降钙素原最大值>2ng/ml、需要肾脏替代治疗、需要有创通气和脓毒性休克被确定为住院死亡率的其他危险因素。
COVID-19 是脓毒症患者住院死亡率升高的独立危险因素。需要有创通气和肾脏替代治疗以及存在脓毒性休克和较高 PCT 应被视为识别高危患者的依据。